Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system.

Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF, Schmidt AM, Brown C, Stern A, LaFaille J, Chess L, Stern DM, Jiang H.

Nat Med. 2003 Mar;9(3):287-93. Epub 2003 Feb 24.

PMID:
12598893
2.
3.

Initiation and regulation of CNS autoimmunity.

Goverman J, Brabb T, Paez A, Harrington C, von Dassow P.

Crit Rev Immunol. 1997;17(5-6):469-80. Review.

PMID:
9419434
5.

The role of costimulation in autoimmune demyelination.

Racke MK, Ratts RB, Arredondo L, Perrin PJ, Lovett-Racke A.

J Neuroimmunol. 2000 Jul 24;107(2):205-15. Review.

PMID:
10854658
6.

Lessons from studies of antigen-specific T cell responses in Multiple Sclerosis.

Martin R, Bielekova B, Gran B, McFarland HF.

J Neural Transm Suppl. 2000;(60):361-73. Review.

PMID:
11205154
7.

Treatment of autoimmune disease by oral tolerance to autoantigens.

Whitacre CC, Gienapp IE, Meyer A, Cox KL, Javed N.

Clin Immunol Immunopathol. 1996 Sep;80(3 Pt 2):S31-9. Review.

PMID:
8811061
8.

Animal models.

Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C.

Ann Neurol. 1994;36 Suppl:S47-53. Review.

PMID:
7517126
9.

What transgenic and knockout mouse models teach us about experimental autoimmune encephalomyelitis.

Fazekas G, Tabira T.

Rev Immunogenet. 2000;2(1):115-32. Review.

PMID:
11324684
10.

Evidence that Fas and FasL contribute to the pathogenesis of experimental autoimmune encephalomyelitis.

Dittel BN.

Arch Immunol Ther Exp (Warsz). 2000;48(5):381-8. Review.

PMID:
11140465
11.
12.

Vaccines for multiple sclerosis: progress to date.

Correale J, Farez M, Gilmore W.

CNS Drugs. 2008;22(3):175-98. Review.

PMID:
18278975
13.

Tolerance and autoimmunity in TCR transgenic mice specific for myelin basic protein.

Goverman J.

Immunol Rev. 1999 Jun;169:147-59. Review.

PMID:
10450515
14.

Protection from autoimmunity by DNA vaccination against T-cell receptor.

Buch T, Waisman A.

Methods Mol Med. 2006;127:269-80. Review.

PMID:
16988460
15.

Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting.

Stinissen P, Raus J.

Acta Neurol Belg. 1999 Mar;99(1):65-9. Review.

PMID:
10218096
16.

Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis.

Stuerzebecher S, Martin R.

Neuroimaging Clin N Am. 2000 Nov;10(4):649-68 ,vii-viii. Review.

PMID:
11359717
17.

T cell receptor peptides in treatment of autoimmune disease: rationale and potential.

Vandenbark AA, Hashim GA, Offner H.

J Neurosci Res. 1996 Feb 15;43(4):391-402. Review.

PMID:
8699526
19.

Mechanisms underlying mast cell influence on EAE disease course.

Brown MA, Tanzola MB, Robbie-Ryan M.

Mol Immunol. 2002 Sep;38(16-18):1373-8. Review.

PMID:
12217411
20.

Insights into the immunopathogenesis of multiple sclerosis.

Hellings N, Raus J, Stinissen P.

Immunol Res. 2002;25(1):27-51. Review.

PMID:
11868933

Supplemental Content

Support Center